Endometrial Cancer Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Endometrial Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “Endometrial Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of endometrial cancer. It projects the future incidence and prevalence rates of endometrial cancer cases across various populations. The study covers age, gender, and type as major determinants of the endometrial cancer population. The report highlights patterns in the prevalence of endometrial cancer over time and projects future trends based on multiple variables.

Endometrial Cancer Understanding: Disease Overview

Endometrial cancer is a malignancy of the uterine lining that primarily affects postmenopausal women. Risk factors include obesity, unopposed estrogen exposure, diabetes, and genetic predispositions such as Lynch syndrome. The disease commonly presents with abnormal uterine bleeding, pelvic pain, or postmenopausal spotting. Early-stage endometrial cancer is often detected through imaging and endometrial biopsy. Histological subtypes, such as endometrioid, serous, and clear cell carcinomas, influence prognosis. Molecular profiling further stratifies patients for targeted therapies, improving personalized treatment approaches and clinical outcomes.

Endometrial Cancer Epidemiology Perspective

The endometrial cancer epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the endometrial cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for endometrial cancer and their trends. The endometrial cancer detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Endometrial cancer ranks as the 15th most common cancer overall and the 6th most common cancer among women globally.
• In 2022, there were approximately 420,368 new cases of endometrial cancer worldwide, making it one of the more common female cancers globally with an age‑standardized incidence rate of about 8.4 per 100,000 women.
• Endometrial cancer predominantly affects women only (biological sex), with incidence rising sharply with increasing age, particularly after age 55-60 years.
• The median age at diagnosis is around 60 years, with the majority of cases occurring in postmenopausal women; women under 40 account for a small minority of diagnoses.

Read more about this report - Request a Free Sample

Country-wise Endometrial Cancer Epidemiology Segment

The endometrial cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Recent evidence from England indicates that the incidence of endometrial cancer is increasing, largely driven by rising obesity and diabetes prevalence and declining hysterectomy rates. The study also reported that South Asian women are diagnosed at a younger average age (around 60 years) compared with White women (around 67 years), highlighting demographic differences and the need for tailored prevention strategies.

In the United States, endometrial cancer is the most common cancer of the female reproductive system and the fourth most common cancer in women. ACS projections estimate about 68,270 new cases in 2026 and approximately 14,450 deaths from these cancers, including uterine sarcomas. About 68 % of uterine cancers are diagnosed at an early stage, often due to symptoms like abnormal bleeding. The average age at diagnosis is 60 years, and incidence continues rising across many racial and ethnic groups. These trends underscore the need for awareness, early detection, and equitable care.

Endometrial Cancer: Treatment Overview

Treatment of endometrial cancer depends on stage and histology. Early-stage disease is primarily managed with surgical intervention, including hysterectomy with bilateral salpingo-oophorectomy, often accompanied by lymph node assessment. Adjuvant therapies may include radiation or chemotherapy, particularly for high-risk histologies or advanced stages. Hormonal therapy with progestins or targeted agents may benefit selected patients with hormone receptor-positive tumors. Emerging approaches include immunotherapy and molecular-targeted therapies, offering personalized options for recurrent or metastatic disease. Lifestyle modifications, such as weight management, may support overall outcomes and reduce recurrence risk.

Key Questions Answered

• What are the key findings of endometrial cancer epidemiology in the 8 major markets?
• What will be the total number of patients with endometrial cancer across the 8 major markets during the forecast period?
• What was the country-wise endometrial cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of endometrial cancer during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of endometrial cancer during the forecast period of 2026-2035?
• What are the currently available treatments for endometrial cancer?
• What are the disease risks, signs, symptoms, and unmet needs of endometrial cancer?

Scope of the Endometrial Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of endometrial cancer based on several factors.
• Endometrial Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The endometrial cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Endometrial Ablation Market

Uterine Fibroids Epidemiology